Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

View:
Post by SupermanLantern on Jan 07, 2016 12:30pm

Partners

So Endo is really still indirectly related to TST according to the website statement:

Telesta Therapeutics has granted Paladin Labs (now part of Endo International plc) an exclusive license to market and distribute MCNA for bladder cancer in Canada, South Africa and Mexico. Telesta Therapeutics will be responsible for all product development and manufacturing costs and Paladin will be responsible for all sales and marketing costs in said territories.

I'm sure if news was to be mentioned "behind closed doors" at the conf. by TST.
(It would be)....

Like others, I have been told by TST mgt. that news will be distributed
at the same time for all investors when it is deemed "news".

TST NR stated they are going over the data from adcom with the partners which seems par
for the course. I'm sure Ipsen brings more to the table then TST does in terms of experience
when dealing with things of this nature "a positive".

IMHO, If the value does move up apprx. 8 days after the JP conf. that will be the smoking gun
but then again so many plays go on..."who knows".

MC80 commentary really brings thing to light in terms of the approval possibilities.
Comment by DamnYankees on Jan 07, 2016 2:01pm
Why would anyone partner with Telesta at this point? The current profile is that of a near dead OTC Pinks hang around that just soundly flunked its Adcomm meeting. What has been done to change that perception in the last 8 weeks? What has been done to demonstrate any remaining value in the company? Forget another partnership, for the sake of MCNA and bladder cancer sufferers it needs to be sold to ...more  
Comment by thathurt on Jan 07, 2016 2:25pm
damn, too funny that is such a retail post i just had to respond...so first as TST  hits $0.39 was it a dead cat bounce or not (who knows not me or you or any other poster, prognosticator, etc.)... so partnering, again no one on this MB has the foggiest idea of whether or not or if never or not...BP will make that decision IMO with only real regard whether they believe MCNA will gain ...more  
Comment by noinstinct89 on Jan 07, 2016 4:09pm
For me, it's still elusive that urologists were the minority at the AdCom. Some people discussed about a drug they will never use. 
Comment by thathurt on Jan 07, 2016 5:22pm
noin, as best i know the structure is pretty dogmatic and as MCNA is oncology and urology it gets both..now i suspect if i remember correctly at least one oncy doc was brain cancer and i betcha if MCNA hadda been brain cancer she woulda voted yes...but i betcha the FDA understands the value of non-practicing advice better than us (ie likely about zero and more opinion than advice)..ps as a ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities